# Ambrisentan

Drug · id `cardio:ambrisentan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: LETAIRIS

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Ambrisentan, sold as Letairis, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening; it also lists a second use, together with tadalafil, that this page does not describe. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause major birth defects. That risk concerns the unborn child and is recorded separately.

## Technical summary

RxNorm ingredient 358274; UNII HW6NV07QEC. MeSH has no descriptor for ambrisentan (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Gilead Sciences, Inc. label for Letairis, application NDA022081 (approved 2007-06-15 as a new molecular entity in Drugs@FDA), effective 2026-06-22 in openFDA. The label's second indication, in combination with tadalafil, is not recorded. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking ambrisentan during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Letairis carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Application number of the label read, NDA022081.
  2. Background: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Effective date of the label text read, 20260622.
  3. Supports: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Label passage quoted in the research quote table (Q-K29-LET-LB-06).
  4. Supports: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Label passage quoted in the research quote table (Q-K29-LET-LB-07).

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Letairis

Recipient: Adult; Population: Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Letairis (ambrisentan tablets, Gilead Sciences, Inc., application NDA022081; the version dated 2026-06-22 in openFDA) describes ambrisentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients to improve exercise ability and delay clinical worsening.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists use in combination with tadalafil; that indication is not recorded here. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a use in combination with tadalafil; that use is not recorded here.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Application number of the label read, NDA022081.
  2. Background: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Effective date of the label text read, 20260622.
  3. Supports: openFDA drug label record for Letairis (ambrisentan tablets), Gilead Sciences, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 725d4e73-6c83-477a-adc6-0ae4a133a844 (manufacturer Gilead Sciences, Inc., application NDA022081), returned on 2026-11-18. The label text is dated 2026-06-22 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22725d4e73-6c83-477a-adc6-0ae4a133a844%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:32Z. Source state: Current. Version fingerprint: cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6.
     How it applies: Label passage quoted in the research quote table (Q-K29-LET-LB-04, Q-K29-LET-LB-05).

## Connected pages

- Ambrisentan is an endothelin receptor antagonist (FDA established pharmacologic class in RxClass): Endothelin receptor antagonists (`cardio:endothelin-receptor-antagonists`)
- FDA label lists pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-letairis-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- The Letairis label lists use in combination with tadalafil as one indication: Tadalafil (`cardio:tadalafil`)

## Provenance

Content hash: a0fd9281afd23fa33eeee526d43f98df57e87d98616b628409c7cdea5062ab84
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
